Osaka University spinoff AnGes said on May 29 that AV-001, an investigational agent being codeveloped with Canadian biotech Vasomune Therapeutics, has earned the US FDA’s fast-track designation for acute respiratory distress syndrome (ARDS). The fast-track tag was granted for the…
To read the full story
Related Article
- New Study of Vasomune-Partnered AV-001 Cleared in Canada: AnGes
September 5, 2025
- AnGes to Invest US$2 Million in Canada’s Vasomune
December 27, 2022
BUSINESS
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
- Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
- Roche PD-L1 Test Approved for Imfinzi in Endometrial Cancer
July 10, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





